The Low DoseThe GLP-1 price desk
Briefing

MEDVi vs Henry Meds

$399/mo against $449/mo for tirzepatide. Which is worth it, and for whom.

Illustration of two objects on a balance scale

Updated 2026-09-18

Both sell tirzepatide. MEDVi costs $399 a month and Henry Meds costs $449, a difference of $50 a month or about $600 a year. The desk reads it as follows.

MEDVi is tablet and injection choice. Henry Meds is sublingual and oral formats. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. MEDVi advertises $399 and bills $399; Henry Meds advertises $399 and bills $449. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

MEDViHenry Meds
Advertised$399$399
Billed$399$449
Gapnone+$50
Per year, billed$4,788$5,388

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

On every attribute we track these two behave identically — same answer on dose pricing, commitment, pharmacy disclosure, formats, insurance and what the price includes. When that happens the decision really is just the monthly figure, and MEDVi is $50 a month cheaper.

What each puts on the record: MEDVi

    Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.

    What each puts on the record: Henry Meds

    • Three-month oral tirzepatide supply $1,047, or $891 paid in full.
    • Three-month oral semaglutide supply $747, or $537 paid in full.

    Where it wins: No membership fee layered on top of medication. Watch for: The advertised "starts at $179" is the sublingual tier. Weekly injectable tirzepatide renews at $449/month.

    In each one’s favour

    MEDVi.

    • Injection pricing is consistent between the first month and renewals.
    • Tablet option for people who will not inject.

    Henry Meds.

    • No membership fee layered on top of medication.
    • Real choice of sublingual, oral tablet and injection.

    Henry Meds scores higher overall at 3 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

    The desk’s call

    The board says MEDVi. What the board cannot say is whether the advertised figures you were shown elsewhere match these — check the gap row, because a listing that advertises low and bills high will beat an honest one in any comparison built on advertised prices.

    The verdict

    On the board, MEDVi at $399 a month is the more defensible choice on arithmetic alone. Henry Meds earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: MEDVi and Henry Meds.

    How they sit against everyone else

    ProgrammeAdvertisedBilledGapVs board floor
    Coreage Rx$149$199+$50+$74/mo
    Trimi$125$125none—
    Ozari Health$125$125none—
    Fifty 410$133$133none+$8/mo

    More from the desk

    • MEDVi tirzepatide review

      Advertised at $399 and billed at $399 — no gap. Position 14 of 18 on our board.

    • Henry Meds tirzepatide review

      Advertised at $399, billed at $449. Position 18 of 18 on our board.

    • How to spot a bad seller

      The FDA sent more than 55 warning letters to online GLP-1 sellers in one day. Here is how to tell a licensed programme from the rest.

    • The twelve-month cost

      Month one is the cheapest month you will have. Here is the full-year arithmetic, including the costs nobody puts in the advert.

    • Cheapest right now

      Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.

    Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure